In this model, B6 mice were injected subcutaneously with B16-OVA tumor cells and then treated 10 days later with either naïve OT-I CD8+ T cells, aAPC-activated OT-I CD8+ T cells, or OT-I CD8+ T cells co-activated with Th1 OT-II CD4+ T cells using MHC I + II aAPCs. This evidence concerns the gene CD8A and neoplasm.